Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The cannabinoid receptor 2 (CB2R) has been linked with the regulation of inflammation, and selective receptor activation has been proposed as a target for the treatment of a range of inflammatory diseases such as atherosclerosis and arthritis. In order to identify selective CB2R agonists with appropriate physicochemical and ADME properties for future evaluation in vivo, we first performed a ligand-based virtual screen. Subsequent medicinal chemistry optimisation studies led to the identification of a new class of selective CB2R agonists. Several examples showed high levels of activity (EC50<200 nM) and binding affinity (Ki<200 nM) for the CB2R, and no detectable activity at the CB1R. The most promising example, DIAS2, also showed favourable in vitro metabolic stability and absorption properties along with a clean selectivity profile when evaluated against a panel of GPCRs and kinases.

Original publication

DOI

10.1016/j.bmc.2014.11.002

Type

Journal article

Journal

Bioorg Med Chem

Publication Date

01/01/2015

Volume

23

Pages

241 - 263

Keywords

Agonist, Cannabinoid receptor 1, Cannabinoid receptor 2, Inflammation, Ligand-based screening, Anti-Inflammatory Agents, Cannabinoid Receptor Agonists, Drug Evaluation, Preclinical, Kinetics, Ligands, Models, Molecular, Receptor, Cannabinoid, CB2, Small Molecule Libraries